Promising Results in Phase 3 Trial of Tumor Treating Fields Therapy

Novocure, an innovative oncology company, announced positive findings from an interim analysis of a Phase 3 clinical trial assessing the safety and efficacy of Tumor Treating Fields therapy. The trial focuses on the treatment of patients with unresectable, locally advanced pancreatic cancer, utilizing a combination of Tumor Treating Fields therapy, nab-paclitaxel, and gemcitabine.

During the trial, an independent data-monitoring committee meticulously reviewed the data obtained from patients enrolled in the study. As a result of their analysis, the committee recommended the continuation of the trial towards final analysis—an encouraging development for Novocure.

To further evaluate the data, Novocure plans to conduct a thorough review in 2024. This comprehensive analysis will provide valuable insights into the effectiveness and potential benefits of Tumor Treating Fields therapy in the treatment of unresectable, locally advanced pancreatic adenocarcinoma.

The Phase 3 trial consists of a randomized, open-label study and includes 556 adult patients with this form of pancreatic cancer. The primary focus of the study is evaluating overall survival. However, other important secondary endpoints encompass progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity.

Novocure continues to pursue groundbreaking advancements in cancer treatment through this Phase 3 clinical trial. The positive results obtained thus far demonstrate the potential for Tumor Treating Fields therapy to significantly impact the lives of patients with unresectable, locally advanced pancreatic cancer.

Contact Chris Wack for more information.